Early Lapatinib-Induced Skin Rash Predicts Better Survival With Lapatinib+Trastuzumab Therapy - Cancer Therapy Advisor

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

PDF) Antibody-Drug Conjugates for the Treatment of Breast Cancer

Lapatinib with trastuzumab for HER2-positive early breast cancer

Great Strides in Precision Medicine: Personalized Oncology

Resistance and Overcoming Resistance in Breast Cancer - Oncology

Lapatinib and lapatinib plus trastuzumab therapy versus

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

Page 1526 – Cancer Therapy Advisor

PDF) A phase II study of afatinib (BIBW 2992), an irreversible

Therapeutic vaccines for breast cancer: Has the time finally come